CommScope Holding And 2 Other Stocks Under $3 Insiders Are Buying

Benzinga ·  Apr 1 19:16

The Dow Jones index closed higher by around 0.1% on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.


  • The Trade: Agrify Corporation (NASDAQ:AGFY) Chairman and CEO Raymond Nobu Chang acquired a total of 1,842,104 shares an average price of $0.38. To acquire these shares, it cost around $699,999.
  • What's Happening: On Feb. 29, Agrify announced a $3.4 million sales order from HarvestWorks Farm.
  • What Agrify Does: Agrify Corp provides hardware and software grow solutions for the indoor agriculture marketplace and provides equipment and solutions for cultivation, extraction, post-processing, and testing for the cannabis and hemp industry.

CommScope Holding

  • The Trade: CommScope Holding Company, Inc. (NASDAQ:COMM) EVP and CFO Kyle David Lorentzen acquired a total of 11,600 shares at at an average price of $1.25. To acquire these shares, it cost around $ $14,500.
  • What's Happening: On March 13, B of A Securities analyst Tal Liani maintained CommScope Hldg with an Underperform and lowered the price target from $2 to $1.
  • What CommScope Holding Does: CommScope Holding Co Inc is a provider of infrastructure solutions for communication, data center and entertainment networks.


  • The Trade: Rezolute, Inc. (NASDAQ:RZLT) Chief Medical Officer Brian Kenneth Roberts acquired a total of 500 shares at an average price of $2.55. The insider spent around $1,275 to buy those shares.
  • What's Happening: On Feb. 13, Rezolute posted a narrower-than-expected quarterly loss.
  • What Rezolute Does: Rezolute Inc is a biopharmaceutical company. The company develops novel, sustained-release injectable therapies.

Don't forget to check out our premarket coverage here

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment